Vistagen Therapeutics Secures $100M Private Placement
Ticker: VTGN · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, private-placement, pipeline-advancement
TL;DR
Vistagen just raised $100M to fund pipeline and PH94B commercialization.
AI Summary
Vistagen Therapeutics, Inc. announced on July 8, 2024, that it has entered into a securities purchase agreement for a private placement of approximately $100 million in gross proceeds. The company plans to use these funds for general corporate purposes, including advancing its clinical pipeline and supporting its commercialization efforts for PH94B.
Why It Matters
This significant capital infusion provides Vistagen with crucial funding to advance its promising drug candidates, potentially accelerating their path to market and benefiting patients.
Risk Assessment
Risk Level: medium — While the capital raise is positive, the company's reliance on clinical trial success and market adoption for its products introduces inherent risks.
Key Numbers
- $100.0M — Private Placement Proceeds (Gross proceeds to fund general corporate purposes, clinical pipeline advancement, and commercialization efforts.)
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- PH94B (drug_candidate) — Product for commercialization
- $100 million (dollar_amount) — Gross proceeds from private placement
- July 8, 2024 (date) — Date of the event
FAQ
What is the primary use of the $100 million in gross proceeds?
The proceeds will be used for general corporate purposes, including advancing Vistagen's clinical pipeline and supporting the commercialization efforts for PH94B.
When did Vistagen Therapeutics announce this private placement?
Vistagen Therapeutics announced the private placement on July 8, 2024.
What is the specific product mentioned for commercialization efforts?
The specific product mentioned is PH94B.
What type of financing did Vistagen Therapeutics utilize?
Vistagen Therapeutics utilized a private placement of securities.
What is the total amount of gross proceeds expected from this private placement?
The company expects approximately $100 million in gross proceeds from the private placement.
Filing Stats: 1,044 words · 4 min read · ~3 pages · Grade level 16.4 · Accepted 2024-07-12 16:27:13
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn20240711_8k.htm (8-K) — 28KB
- ex_697397.htm (EX-16.1) — 1KB
- i991.jpg (GRAPHIC) — 100KB
- 0001437749-24-022667.txt ( ) — 297KB
- vtgn-20240708.xsd (EX-101.SCH) — 3KB
- vtgn-20240708_def.xml (EX-101.DEF) — 11KB
- vtgn-20240708_lab.xml (EX-101.LAB) — 15KB
- vtgn-20240708_pre.xml (EX-101.PRE) — 11KB
- vtgn20240711_8k_htm.xml (XML) — 3KB
01 Change in Registrant ' s Certifying Accountant
Item 4.01 Change in Registrant ' s Certifying Accountant (a) Dismissal of Independent Registered Public Accounting Firm On July 8, 2024, following the completion of a competitive selection process conducted by the Audit Committee of the Board of Directors (the " Audit Committee ") of Vistagen Therapeutics, Inc. (the " Company ") to determine the Company's independent registered public accounting firm for the fiscal year ending March 31, 2025, the Company selected KPMG LLP (" KPMG ") to serve as the Company's new independent registered public accounting firm, effective as of such date, and notified WithumSmith+Brown, PC (" Withum ") of its dismissal as the Company's independent registered public accounting firm effective as of that date. Withum's reports on the Company's consolidated financial statements for each of the Company's fiscal years ended March 31, 2024 and March 31, 2023 did not contain any adverse opinion or a disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope, or accounting principles, except that Withum's audit report for the fiscal year ended March 31, 2023 included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2023 and filed with the Securities and Exchange Commission (the " SEC ") on June 28, 2023, contained an explanatory paragraph disclosing uncertainty regarding the Company's ability to continue as a going concern. Withum's audit report for the Company's fiscal year ended March 31, 2024 and filed with the SEC on June 11, 2024, did not contain such explanatory paragraph. During each of the Company's fiscal years ended March 31, 2024 and March 31, 2023, and the subsequent interim periods through the date of dismissal, there were no "disagreements," as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions, between the Company and Withum on any matter of accounting principles or practices, financial statement disclosure or auditin
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits . (d) Exhibits Index Exhibit No. Description 16.1 Letter from WithumSmith+Brown, PC, dated July 10, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: July 12, 2024 By: /s/ Cynthia L. Anderson Cynthia L. Anderson, CPA Chief Financial Officer